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Recent evidence has suggested that dietary polyunsaturated fatty acids (PUFAs) modulate
inflammation; however, few studies have focused on the pathobiology of PUFA using isocaloric
and isolipidic diets and it is unclear if the associated pathologies are due to dietary PUFA
composition, lipid metabolism or obesity, as most studies compare diets fed ad libitum. Our
studies used isocaloric and isolipidic liquid diets (35% of calories from fat), with differing
compositions of omega (ω)-6 or long chain (Lc) ω-3 PUFA that were pair-fed and assessed
hepatic pathology, inflammation and lipid metabolism. Consistent with an isocaloric, pair-fed
model we observed no significant difference in diet consumption between the groups. In contrast,
the body and liver weight, total lipid level and abdominal fat deposits were significantly higher in
mice fed an ω-6 diet. An analysis of the fatty acid profile in plasma and liver showed that mice on
the ω-6 diet had significantly more arachidonic acid (AA) in the plasma and liver, whereas, in
these mice ω-3 fatty acids such as eicosapentaenoic acid (EPA) were not detected and
docosahexaenoic acid (DHA) was significantly lower. Histopathologic analyses documented that
mice on the ω-6 diet had a significant increase in macrovesicular steatosis, extramedullary
myelopoiesis (EMM), apoptotic hepatocytes and decreased glycogen storage in lobular
hepatocytes, and hepatocyte proliferation relative to mice fed the Lc ω-3 diet. Together, these
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results support PUFA dietary regulation of hepatic pathology and inflammation with implications
for enteral feeding regulation of steatosis and other hepatic lesions.

Keywords
Diet; PUFA; Omega-3; Hepatic Steatosis; Fish Oil; Fatty Liver

1 Introduction
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Omega-6 (ω-6) and omega-3 (ω-3) polyunsaturated fatty acids (PUFA) are essential fatty
acids (FA), which cannot be interconverted in humans due to lack of ω-3 desaturase.[1]
Besides their role in energy storage and production, PUFA are important constituents of
biological membranes and are precursors to prostaglandin and pro-resolving lipid mediator
pathways.[2],[3] Many lipid mediators derived from ω-6 PUFA have pro-inflammatory
functions,[4] whereas; those synthesized from ω-3 PUFAs have anti-inflammatory
properties.[5, 6] Both ω-3 and ω-6 PUFA are metabolized by the same enzymes resulting in
signaling molecules with opposing bioactivities. Studies have suggested that humans
evolved on a diet containing approximately a 1:1 ratio of ω-6:ω-3 PUFA[7]; however,
current western diets has a high ω-6:ω-3 ratio.[8] A diet high in ω-6 PUFAs, such as linoleic
acid (LA), results in decreased tissue levels of ω-3 long-chain (Lc) PUFAs, including
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)[9], and a heightened risk of
chronic inflammatory disease processes.[10] In contrast, a diet containing a low ω-6:ω-3
PUFA ratio, or one that is supplemented with Lc ω-3 PUFAs, reduces risk factors for
chronic inflammatory diseases, including cardiovascular disease,[11, 12] cancer,[13, 14] and
obesity.[15, 16] Dietary Lc ω-3 PUFA can also reduce hepatic inflammation, fibrosis, and
steatosis in non-alcoholic fatty liver diseases (NAFLD), and non-alcoholic steatohepatitis
(NASH).[17, 18]
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Although hepatic lipid storage is normal, excessive intrahepatic lipid accumulation (>5.6%
of liver weight) [19] is associated with steatosis, inflammation and cardiometabolic
syndromes. Several mechanisms are involved in the accumulation of intrahepatic lipids,
including increased accumulation of triglycerides in the liver, increased de novo lipogenesis,
and/or reduced clearance and obesity.[20] Approximately 30% of Americans have a fatty
liver, [19] and this is increased up to 75% amongst obese individuals.[21] Further, hepatic
steatosis occurs rapidly with excess calorie consumption, independent of dietary
composition.[22] In contrast, in humans a hypocaloric diet reduces steatosis,[23, 24]
suggesting that it is crucial to differentiate between the effects mediated by total caloric
intake versus obesity to understand the role of dietary composition in the modulation of the
hepatic microenvironment. The majority of studies on hepatic steatosis have used high-fat
diets (60% of calories from saturated fatty acids (SFAs)) and overfeeding to provide an
animal model of NAFLD.[25, 26] To date, little is known about the effects of ω-6 and ω-3
PUFA dietary composition, independent of caloric intake on the hepatic microenvironment.
Mature myeloid cells are terminally differentiated and continuously renewed by the
proliferation of committed hematopoietic precursors, such that myelopoiesis is critical to
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expand and replenish the myeloid cell pool. Numerous pathologic conditions stimulate
myelopoiesis including, infections, autoimmune and inflammatory conditions, neoplasia and
obesity in association with neutrophilia, splenomegaly and multifocal, hepatic
extramedullary myelopoiesis (EMM), i.e. the formation of myeloid tissue outside of the
bone marrow.[27] Hepatic EMM is normal during fetal and early development;[28, 29]
however, EMM in adult tissues is associated with pathological conditions. Hepatocyte
apoptosis indicates liver injury and found significantly increased in patients with NASH.[30]
High fat diets have also been reported to increase the osmotic fragility of red blood cell
(RBC) membranes resulting in decreased RBC counts and hemoglobin concentration.[31]
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In the present study, we used an isocaloric, isolipidic liquid diet combined with pair feeding
that allows for controlled dietary caloric intake and limited weight changes between groups.
Using this model, we examined the effects of dietary ω-6 and ω-3 PUFA composition on
hepatic pathobiology and report that dietary PUFA composition regulates hepatic steatosis,
proliferation, apoptosis and EMM using a dietary model containing comparatively lower fat
calories as a percent of total relative to previously reported studies.[25, 26]

2. Materials and Methods
2.1. Animals and Pair-fed Model

Author Manuscript

Female BALB/c mice (6 weeks old) purchased from Charles River Laboratories were
housed in micro-isolators in groups of five mice per cage, under standard conditions of
temperature and humidity, with a 12 h light-dark cycle. The micro-isolators were attached to
high efficiency particulate air (HEPA)-filtered ventilation blowers for clean air. The animal
housing facility was maintained as a specific pathogen free (SPF) area. The Institutional
Animal Care and Use Committee at the University of Nebraska Medical Center approved the
animal protocol for the study.
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After 2 weeks of acclimation (Fig. 1A) to each diet, mice were divided at random into two
dietary groups (n=20) on the basis of the experimental liquid diet (ω-6 or ω-3 diet). Our
diets were isocaloric and isolipidic and had identical protein, fiber, and micronutrient
contents. The ω-6 diet was the Lieber-DeCarli control diet (Dyets # 710027) containing 28.4
gm/L olive oil, while the ω-3 diet was customized by using the base diet (Dyets # 710166)
and adding 8.4 gm/L olive oil and 20 gm/L of encapsulated fish oil (NutriGold Triglyceride
Omega-3 Gold capsules; Lot# 0081-3180-2) (Table 1). Both liquid diets provided 1.0 Kcal
energy per ml of diet and equal calories from macronutrients (35% derived from fat, 47%
from carbohydrate, and 18% derived from protein). The ω-6 and ω-3 diets differed primarily
by the absence or presence of Lc ω-3 PUFA from fish oil and ω-6 PUFA from olive oil
respectively. Omega-3 capsules and Lieber-DeCarli powder diets were stored at 4°C. Diets
were prepared and delivered every 24-26 hours and daily intake was monitored. Ad libitum
access to the liquid diets was provided for the first 5 days to acclimatize the mice to the
diets. From day 6, the ω-6 diet group mice were pair-fed based on mean consumption of the
ω-3 diet group from the previous day and this was continued throughout the study for 10 or
20 weeks. Body weights were recorded twice a week. At the end of the experiment, blood
was collected without fasting prior to the mice being euthanized and hematological
parameters, such as total white blood cells count (WBC) count, red blood cells (RBC) count,
J Nutr Biochem. Author manuscript; available in PMC 2019 February 01.
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hemoglobin level, hematocrit and mean corpuscular volume (MCV) were determined by vet
ABC animal blood counter (Scil animal care company, Grayslake, IL). Livers and abdominal
adipose tissue were removed and weighed and the livers processed as described below. In
addition, a limited number of control studies were undertaken with age matched, chow fed
(#7912, Teklad) mice as a baseline control.
2.2. Fatty Acid Analysis
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Portions of liver tissues and plasma samples from the diet fed mice for 10 weeks were snap
frozen and stored at -80°C for FA analysis. Portions of ready-to-use ω-3 and ω-6 diets were
also frozen until needed for lipid extraction. Omega-3 capsules were stored at 4°C and used
directly for FA analysis. Total lipid extraction from tissues and diets were undertaken using
antioxidant β-hydroxy-toluene (0.05%, wt/vol) as previously described.[32, 33]
Heptadecanoic and nonadecanoic acid (100 μg each) were added to all samples to estimate
the recovery of FA. Complex lipids were hydrolyzed by adding 0.5 ml of methanol
containing 1% (wt/vol) sulfuric acid and 0.25 ml of toluene, and then were incubated at
60°C overnight. Following incubation, 1.25 ml of water containing sodium chloride (5%, wt/
vol) was added and esters were extracted using hexane (2 × 1.25 ml per sample). The hexane
layer was washed using 1 ml of water containing potassium bicarbonate (2%, wt/vol), and
dried over anhydrous sodium sulfate. The solvent was removed under a stream of nitrogen
and the FA methyl esters were analyzed by gas chromatography-mass spectrometry (GCMS) using an Agilent 6890 series gas chromatograph equipped with a 5873 mass-selective
detector. For assessment of sterols, 100 μg of 5α-cholestane was added to samples as an
internal standard. Sterols were separated and detected by GC-MS using a DB-17ms column.
FA concentration was analyzed as μg/μl or μg/mg of the samples, analyzed, and compared
between the diets and tissues from ω-3 and ω-6 diet fed mice
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2.3. Histology and immunohistochemistry (IHC)
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Liver tissues were fixed in zinc fixative for 24-48 hours, and transferred to 70% ethanol,
prior to paraffin embedding, and sectioned at 4-6 μm. For Oil Red O (ORO) staining, fresh
liver tissues were embedded in optimal cutting temperature (O.C.T) compound medium
(Tissue-Tek #4583, Sakura Finetek, CA U.S.A) and stored at -80°C until sectioned and
stained. Sections were stained with hematoxylin and eosin (H & E), examined under light
microscopy using a Zeiss Axioplan-2 microscope with a HRc camera, and analyzed using
Zeiss AxioVision Rel 4.8 software. Two persons examined the sections as “blinded” group
assignments and an experienced pathologist validated the results. Steatosis was examined in
H & E stained sections, then further confirmed and quantified by counting ORO stained lipid
droplets in hepatocytes. Lipid droplets the size of a hepatic nucleus or larger were
enumerated to analyze macro-vesicular steatosis, whereas smaller lipid droplets were
considered for micro-vesicular steatosis analysis. To quantify hepatic steatosis, the number
of lipid droplets per 1000× magnification field were counted for 10 random fields for each
mouse liver. EMM was assessed based on foci of immature inflammatory cells and their
nuclear morphology in H & E stained sections. The number of foci per field and the number
of inflammatory cells per focus were counted in 10 fields at 200× magnification. Biliary
duct size and the area of biliary epithelium were measured in the biliary ducts present in 10
random fields at 200× magnification using Image-J software. Hepatic glycogen deposition
J Nutr Biochem. Author manuscript; available in PMC 2019 February 01.
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was measured using Periodic Acid-Schiff (PAS) staining on paraffin embedded liver tissue
sections. Magenta color PAS positive hepatocytes were confirmed as glycogen deposited
hepatocytes by comparing glycogen degradation in a serial section treated with PAS-diastase
(PAS-digest). The average number of PAS-positive hepatocytes were counted in 10 fields of
lobular regions (200×).
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Rabbit polyclonal antibody to CD45 (ab10558 Abcam Inc, Cambridge, MA) and rabbit
monoclonal antibody to Ki67 (ab16667, Abcam Inc.) were used to detect leukocytes and
proliferation markers respectively. For IHC staining, deparaffinized and rehydrated liver
sections were steamed in preheated sodium citrate antigen retrieval buffer (pH 6.0) for 20
minutes using a steamer (HS1000, Black and Decker, Miramar, Florida), slides were cooled,
washed 3 times in TRIS-buffered saline, pH 7.6 (TBS) containing tween-20 (TBST),
endogenous peroxidase blocked by hydrogen peroxide, washed in TBST and blocked with
5% goat serum in TBST (ab7481; Abcam Inc.) for 1 hour at room temperature (RT).
Primary antibodies were diluted in antibody diluent (BD559148; BD), and incubated at 4°C
overnight. For negative controls, serial sections were incubated in the diluent without the
primary antibody and all other staining aspects undertaken. Sections were washed 3 times
with TBST and incubated in Signal Stain Boost IHC detection reagent (HRP, Rabbit 8114S
Cell Signaling Technology; Danvers, MA.) for 30 minutes at RT in a humid chamber. The
washed sections were incubated with DAB chromogen (BD550880; Becton Dickinson, New
Jersey) until a mild brown color was detected. Sections were briefly dipped in a hematoxylin
solution (MHS32; Sigma-Aldrich, St. Louis, MO) followed by 0.1% sodium bicarbonate for
counter staining. Images were captured on a Zeiss Axioplan-2 microscope as described
above. The number of CD45+ cells in each cluster, and the number of clusters of CD45+
cells per 100× field were counted in 10 random fields per sample (n=5).
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2.4. TUNEL Labeling
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The terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate nick
end labeling (TUNEL) assay was performed on deparaffinized liver sections according to the
manufacturer's instructions (Roche, Indianapolis, IN). The label solution without TdT was
used as a negative control and liver sections with known tumor metastases were used as
positive controls. Slides were cured overnight, in the dark, with ProLong® Diamond
Antifade Mountant with DAPI (P36971; Thermo-Fisher, Grand Island, NY). Fluorescent
images were captured on a Zeiss LSM-710 confocal microscope at 630× magnification, and
the images were processed using the Zeiss Zen 2012 stitching software and merged into a
single image. The number of TUNEL positive nuclei and DAPI positive hepatic nuclei per
field at 630× magnification were counted in 10 random fields to calculate the number of
apoptotic nuclei and relative percentage of apoptotic hepatocytes.
2.5. Protein extraction of hepatic lysate and western blotting
Freshly isolated liver sections were collected in ice-cold Tissue Protein Extraction Reagent
(T-PER™; #77510; Thermo-Scientific, Grand Island, NY) containing complete™ ULTRA
Tablets, EDTA-free, Protease Inhibitor Cocktail (#5892953001, Roche, Indianapolis, IN)
and PhosSTOP™ phosphatase inhibitor cocktail (#04906837001, Roche, Indianapolis, IN),
and then homogenized using tissue homogenizer with disposable tips (Omni TH; Omni
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International, Kennesaw, GA). The homogenized tissues were centrifuged at 10,000g for 10
minutes at 4°C. Protein concentrations of the whole tissue extracts were determined
according to the manufactur's protocol (Pierce™ BCA Protein Assay Kit; #23227, ThermoFisher, Grand Island, NY). For Western blotting, whole cell protein samples were separated
by SDS PAGE using a 4-15% Mini-PROTEAN TGX Precast Gel (456-1084, Bio-Rad), and
blotted using the Trans-Blot® Turbo™ Mini PVDF Transfer Packs (1704156, Bio-Rad)
Trans-Blot® Turbo™ Transfer System (Bio-Rad, Hercules, California). The blotted
membranes were blocked using 5% BSA in TBST for 1 hour at RT, followed by incubation
in diluted primary antibodies anti-NF-kB p65 [E379] (ab32536), anti-beta Actin (ab8227)
overnight at 4°C. After washing 3 times, blots were incubated with the secondary antibody
[goat anti-rabbit IgG H&L chain, HRP] (ab6721, Abcam Inc.) for 1 hr at RT. All the
antibodies were purchased from Abcam Inc. The protein bands were examined by using
SuperSignal™ West Pico Chemiluminescent Substrate (34078, Thermo-Fisher, Grand
Island, NY). Blots were exposed and digital images were acquired using a myECL™
Imager, and relative protein quantities were determined by using myImageAnalysis™
Software (62237, Thermo-Fisher, Grand Island, NY).
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2.6 Flow cytometry and colony forming units-granulocyte, macrophage (CFU-GM)
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Freshly isolated livers were minced into small pieces, treated with collagenase-IV
(17104-019, Gibco) and DNAse I (D5025, Sigma), and filtered through cell dissociation
sieve to prepare a single cell suspension. Hepatic leukocytes (WBCs) were isolated using
mouse cell separation media, Lympholyte M (CL5035, Cedarlane). Then the total hepatic
WBC count was analyzed using vet ABC animal blood counter and data presented as WBC
count/gram of the liver. For flow cytometry, isolated leukocytes were stained with the
indicated antibodies for 30 minutes at 4°C. The antibodies used were anti-CD45-V450
(clone 30-F11, BD Pharmingen) anti-CD201-APC (clone ebio1560, ebioscience) and antiCD27-BV650 (clone LG3A10, BD Pharmingen). Flow cytometry was performed on BD
LSRFortessa ×50 platforms and results were analysed using FlowJo software version 9.9.5
(TreeStar). For CFU-GM assay, 105 cells were cultured in 1.1 ml of methylcellulose-based
medium for myeloid progenitor cells (MethoCult™ GF M3534, STEM cell technologies) as
per company protocol. Colonies of at least 50 cells were scored for analysis of CFU-GM.
2.7. Statistical Analysis
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Results were expressed as mean +/- standard error of mean (SEM) for animal weights, liver
weight, liver weight/body weight, abdominal fat weight, abdominal fat weight/body weight,
fatty acid levels, histology and IHC quantification values. Data from the two groups was
compared by Student's t-test for independent samples. Plots for change in body weights were
compared by repeated measures test. All graphs were plotted using Sigma Plot software. All
data was analyzed using SPSS. Data differing by p≤0.05 were considered to be significant.

3. Results
3.1. Pair-feeding, food consumption and body weight
During the initial 5-day ad libitum diet acclimation period (Fig. 1A), mice on the ω-6 diet
consumed more feed than those in the ω-3-diet group (p<0.05). Therefore, when pairJ Nutr Biochem. Author manuscript; available in PMC 2019 February 01.
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feeding was initiated on day 6, the average amount of ω-3 diet consumed was used as the
baseline for the ω-6 diet (Fig. 1B). Studies of changes in body weight over time with the
isocaloric and isolipidic diets using a repeated measures test revealed significant increases in
weight in the mice (n=20/group) given the ω-6 diets (Fig. 1C). In part due to the increased
consumption of the ω-6 diet during a brief acclimation period a significant difference in
body weight was observed between the groups on day 5 (Fig. 1D). Similarly, at the pairfeeding mid points (day 20, and day 40) and at autopsy on day 69 (Fig. 1D) significant
differences in body weights were also observed. Consistent with the higher body weights at
autopsy (20 weeks) mice fed the ω-6 diet had significantly more abdominal fat (Fig. 1E) and
abdominal fat weight relative to the body weight (Fig. 1F) as compared to ω-3 diet fed mice.
On gross examination of the livers from the ω-3 (Fig. 1G) and ω-6 diet fed mice (Fig. 1H),
livers from ω-6 diet fed mice were lighter in color (pink) and significantly smaller than those
from the ω-3 fed mice, which were red-brown in color (Fig. 1H). In both groups liver
weights (Fig. 1I) and liver:body weight ratios (Fig. 1J) were significantly lower in mice fed
the ω-6 diet.
3.2. Effect of PUFA diet composition on the lipid profile of plasma and liver
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The lipid composition of the plasma and livers were analyzed following autopsy at 10 weeks
post dietary initiation (Table-2). These studies revealed an 8-fold higher level of AA (0.64
μg/μl) in the plasma of ω-6 fed mice. However, as the ω-6 diet contained no AA (C20:4); the
AA is of a metabolic origin from the ω-6 PUFA precursor, linoleic acid (C18:2), which is
contained in both diets. Both of the diets and the plasma of mice on these diets had a
comparable level of C18:2, but AA product:precursor ratio (C20:4/C18:2) was 5.8 fold
higher in the plasma of ω-6 diet fed mice. Further, there was a 2.8-fold higher level of total
ω-6 FAs in the plasma of ω-6 diet fed mice compared to ω-3 diet fed mice (p<0.05); even
though both of the diets had comparable amounts of total ω-6 PUFAs. In contrast to ω-6 FA
levels, the ω-3 PUFA, EPA was not detected in the plasma or livers of mice consuming the
ω-6-diet. Similarly, levels of the ω-3 PUFA, DHA were 2.8-fold lower (0.05 vs. 0.14 μg/μl)
in the plasma of mice fed the ω-6 diet (p<0.05). There were also 1.9-fold and 2.4-fold
increase in the level of linoleic acid and AA respectively in the liver, resulting in a
significantly higher level of total ω-6 PUFA in livers of ω-6 diet fed mice as compared to
ω-3 diet fed mice (p<0.05). However, the C20:4:C18:2 FA ratio was not significantly
different between the livers of ω-6 vs. ω-3 diet fed mice. Consistent with the plasma EPA
levels, EPA was not detected in the livers of mice fed the ω-6 diet and the DHA content was
significantly (11-fold) lower (1.5 vs. 16.5 μg/mg), compared to mice fed the ω-3 diet
(p<0.05). We note that the mono unsaturated fatty acid (MUFA) content was significantly
higher in the liver, but not in plasma of mice fed the ω-6 diet. Table 2 also has an analysis of
the FA composition of the fish oil used in the diet, which contained 83.2% of total FAs in the
form of ω-3 FA (from C20:5 and C22:6) resulting in a ω-6:ω-3 FA ratio of 0.7:1 in the ω-3
diet compared to 21:1 in the ω-6 diet. The ω-6: ω-3 FA ratios of the plasma was similar to
the dietary ratio.
3.3. Effect of dietary ω-3:ω-6 PUFA hepatic histopathology and steatosis
Histopathologic analysis of H & E stained liver sections from mice fed the different diets for
10 weeks (Fig. 2A) revealed significant effects on hepatocyte steatosis. The livers from mice
J Nutr Biochem. Author manuscript; available in PMC 2019 February 01.
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fed the ω-3 diet had occasional hepatocyte lipid microvacuoles; whereas mice on the ω-6
diet had an increase in macro- and micro-vesicular steatosis in their hepatocytes (Fig. 2A).
Steatosis was quantified by counting the ORO positive fat droplets that were about the size
of a hepatic nucleus. There was a 7-fold increase in macrovesicular steatosis in mice fed the
ω-6 diet, compared to the ω-3 diet fed mice (p<0.05) (Fig. 2B and 2C). Moreover, an
increase in microvesicular steatosis was observed in the livers of ω-6 diet fed mice (Fig.
2C). This suggested that the increase in the dietary hepatic ω-6:ω-3 ratio in mice receiving
the ω-6 diet (Table 2) enhanced hepatic macro-steatosis, independent of total caloric
consumption.
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Hepatic glycogen storage was assessed by the histological analysis of PAS (+/- diastase
digestion) stained liver sections of mice fed the diets for 20 weeks (Fig. 3). The result
showed that livers from mice fed the ω-3 diet had significant glycogen storage in
hepatocytes around portal triad and central vein of hepatic lobules, which was absent in mice
fed the ω-6 diet (Fig. 3A-3C). The presence of glycogen deposits in PAS positive cells was
confirmed by a comparison to a serial section that underwent glycogen digestion (Fig. 3C).
Thus, the results indicate that the dietary ω-6:ω-3 FA ratio might modulate energy storage
and metabolism pathways such that increasing consumption of a diet with a high ω-6:ω-3
FA ratio enhances hepatic fat storage whereas consumption of Lc ω-3 FA reduces fat storage
but enhances energy storage in the form of glycogen. Collectively, the increase in the dietary
ω-6:ω-3 FA ratio results in macrosteatosis, and decreased glycogen deposition in lobular
hepatocytes. We also undertook a histological analysis of liver tissue from mice fed a chow
control diet using H & E and ORO stained sections (Fig. S1 (A-C)). The histological
features of livers from chow controls were distinct from the mice receiving liquid diets and
had intermediate level of steatosis (more than the ω-3 group but less than the ω-6 group.
Also, there were a few microgranulomas in the liver from chow fed mice but the size,
number and features of those immune cells were distinct than what we reported as EMM in
this study (Fig. S1B). Thus, mice in a chow control group were not used in further analysis
as their dietary composition had multiple differences from our experimental liquid diets
including lipid types, percentages, protein and carbohydrate levels and calories consumption.
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The total WBC count of blood and liver was determined. There was no significant difference
in the peripheral blood WBC count between the dietary groups, i.e.; 11.3 × 106 +/- 1.1 × 106
and 9.3 × 106 +/- 1.0 ×106 WBC cells per ml of blood in mice from ω-3 and ω-6 diet groups
respectively (n=20). In contrast, mice fed ω-6 diet had a significant (10-fold) increase in the
number of WBC cells per gram of liver (7.9 × 106 +/- 1.3 × 106) compared to ω-3 diet fed
mice (0.8 × 106 +/- 0.5 × 106). We also evaluated hepatic inflammatory cell infiltration by H
& E and anti-CD45 staining from mice receiving the diets for 10 and 20 weeks (Fig 4A-4G).
The differentiated inflammatory cells were observed in cellular clusters composed of
immature myeloid cells with variable size and nuclear morphology (Fig. 4A), supporting
hepatic EMM. Mice given the ω-6 diet for 10 weeks had a significant (9-fold) increase in
EMM foci (0.9+/-0.2 per 100× magnified field), compared to ω-3 diet fed mice (Fig. 4A and
4B). Similarly, mice given the ω-6 diet for 20 weeks had an inflammatory appearance, with
significantly higher number of EMM foci (2-fold) compared to ω-3 diet fed mice
(0.2+/-0.06 per 100× magnified field) (Fig. 4B). However, there was no significant
difference in the number of EMM foci between the 10- or 20-week diet fed groups (Fig. 4B).
J Nutr Biochem. Author manuscript; available in PMC 2019 February 01.
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Further, the EMM foci in ω-6 fed mice were larger and located adjacent to the central veins,
whereas the EMM foci in ω-3 diet fed animals were smaller and located randomly in the
hepatic sinusoids (Fig. 4A). The presence of inflammatory cells (individually distributed or
in clusters) was confirmed by staining the liver sections with the anti-CD45 antibody (Fig.
4C - 4G). The ω-6 diet fed mice had significantly higher numbers of individual CD45+ cells
compared to the ω-3 diet fed groups, in both the 10 and 20 weeks' diet fed studies (Fig. 4C
& 4D). Morphologically, these CD45+ cells included both myeloid and lymphoid cells. In
addition, ω-6 diet fed mice had a significantly higher number of CD45+ inflammatory cell
foci (6.8+/0.4) compared to ω-3 diet fed mice (0.4+/-0.3 per 100× magnified field). The foci
were approximately 3 times larger (23.2+/-2.4 cells/cluster) in the livers of ω-6 diet fed mice
compared to the ω-3 diet fed mice (8+/-5.3 cells/cluster) (Fig. 4E-4G). Similar results were
observed in the livers of mice maintained on the diets for 20 weeks. Additionally, the
number of inflammatory cells per EMM foci were significantly increased in the 20-week
diet fed mice compared to the 10-week mice when studied using mice from both dietary
groups. (Fig. 4F and 4G). Confirmation of the increase in hepatic hematopoietic progenitor
(CD201+CD27+) cells [34] was obtained by flow analysis of isolated hepatic nonparenchymal cells and found as a 24.4+/-4.9% of CD45+ cells in ω-6 diet fed mice versus
3.7+/-1 % of CD45+ cells in ω-3 diet fed mice were of progenitor phenotype respectively.
The myeloid phenotypes of progenitor cells were further confirmed by CFU-GM analysis,
which showed that ω-6 and ω-3 dietary groups had 14.9+/-1.1 and 9.4+/-2.1 CFU-GM
colonies/100,000 cells plated respectively.
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Since NFκB expression is associated with myelopoiesis, we examined the expression of
NFκB protein in the livers of mice fed the diets for 10 weeks and found that livers from ω-6
diet fed mice had a significantly higher level of NFκB expression (Fig. 4H and Fig. 4I)
(p<0.05, n=5), indicating inflammatory cell activation. Collectively, the higher ω6:ω3 FA
ratio in the diets appeared to be associated with inflammation and EMM in the hepatic
microenvironment.
3.4. Dietary ω3:ω6 PUFA regulation of hepatocyte proliferation, degeneration, and
apoptosis
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We examined hepatocyte proliferation (Ki67) and apoptosis (TUNEL) by IHC using mice
fed the experimental diets for 10 or 20 weeks. Mice fed the diet for ten weeks did not have a
difference in hepatocyte proliferation (data not shown). However, mice fed the ω-6 diet for
20-weeks had a significantly lower number of proliferating hepatic nuclei (1.5-fold) as
compared to ω-3 diet fed animals (Fig. 5A and 5B). In contrast to hepatocyte proliferation, a
4-fold increase in the number of TUNEL positive hepatocyte nuclei was observed in the
livers of mice fed the ω-6 diet for 20 weeks (Fig. 5C and 5D). When the number of TUNEL
positive nuclei relative to total hepatocyte nuclei were compared, a significantly higher
frequency of hepatocytes in the livers of ω-6 diet fed mice were TUNEL positive (41%) as
compared to 15% of the hepatocytes in the livers of ω-3 diet fed mice (Fig. 5E).
Collectively, these results suggest a potential mechanism for the decrease in liver weight in
the ω-6 diet fed animals.
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Additionally, morphological differences were observed in the bile ducts of ω-3 versus ω-6
diet fed mice (Fig. S2).

4. Discussion
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In the present study, we compared the biological effects of feeding ω-3 versus ω-6 PUFA
using Lieber-DeCarli, isocaloric liquid diets and a pair-fed model. During acclimatization,
the dietary preference was for the ω-6 diet, which was consistent with our earlier
observations. Thus, the ω-3 diet consumption was used as the base-line for pair feeding. In
contrast to prior reports of pair-fed mice given isocaloric diets,[35, 36] in our studies
significant differences in body weight were observed between mice fed an isolipidic ω-3
versus ω-6 diet. It is noted that in the referenced prior studies, diets differed in components
other than PUFA and so are not directly comparable. This is relevant as in the one published
study, in which mice were pair fed, isocaloric and isolipidic diets differing in PUFA
composition (safflower oil (ω-6) versus fish oil (ω-3)) mice on the safflower oil diet for nine
months had a 31% increase in weight versus mice on the fish oil diet.[37] These
observations support a need for pair-feeding to achieve an isocaloric diet due to dietary
preferences by laboratory rodents, and a need for isolipidic diets to study PUFA regulation
of body weight. Further, despite providing isocaloric and isolipidic diets, we observed a
significant difference in fat mass measured as abdominal fat in ω-6 diet fed mice, suggesting
differential metabolism between the two groups. This is consistent with prior reports of
PUFA regulation of dietary fat content and body fat deposition and distribution.[38, 39] In
one clinical study, consumption of PUFA diets was reported to decrease visceral fat and
increase lean muscle mass as compared to individuals receiving high saturated fat diets.[38]
Among the subtypes of PUFA, ω-3 can limit hypertrophy of abdominal fat deposits[40] and
reduce weight gain in pre-obese animals and humans by a reduction in visceral fat[41-44].
Potential mechanisms for the divergent effects of ω-3 and ω-6 FAs in adipose tissue biology
include the regulation of adipogenesis,[45] lipid homeostasis,[46] brain-gut-adipose tissue
axis,[47] and systemic inflammation,[48] suggesting that lowering the dietary ω-6:ω-3 ratio
might help control obesity.[49] The level of Lc ω-3 PUFA used in this study was higher than
the dose used in clinical study [50], because the current study was primarily designed to
analyze the effects of a ω-6: ω-3 ratio of 1:1, which has been reviewed in literatures as the
ω-6: ω-3 ratio upon which humans evolved. [7]
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The FA composition of diets can modulate the composition of stored and structural lipids;
[51] including the FA profile of plasma and tissues.[52] [53] In the present study, we
observed a significant increase in total ω-6 PUFA, AA, and a decrease in DHA, and an
absence of EPA in the plasma of mice fed a ω-6-diet. These observations are in agreement
with a previous report, in which rats were fed a diet with a 1:1 ratio of ω-6:ω-3 FA resulting
in a significantly higher levels of plasma EPA, DHA, and a lower level of AA compared to
the rats fed a diet with a 30:1 ratio of ω-6:ω-3 PUFA.[52] The results are also consistent
with a clinical study in which the plasma FAs in humans were associated with their dietary
FA composition.[54]
Our results suggest that the plasma level of Lc ω-3 PUFA, such as EPA and DHA, reflect
dietary intake. In contrast, plasma AA (C20:4) levels could only be explained by the
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elongation and desaturation of the ω-6 linoleic acid (C18:2) in mice given the ω-6 diet.
Further, the ω-6 and ω-3 PUFAs compete for incorporation into phospholipids and as
substrates contributing to these differences.[55] In this study, the concentration of total ω-6
PUFAs and linoleic acid (precursor to AA) did not differ between the experimental diets,
although the AA: precursor linoleic acid was 5.8-fold higher in the plasma of mice fed ω-6
diets. Thus, the decreased level of plasma AA in the ω-3 diet fed mice is apparently
regulated by dietary ω-3 Lc PUFA, as a modulator of AA biosynthesis. This observation is
supported by reports that both EPA and DHA can reduce proinflammatory cytokines[56] and
hepatic steatosis.[57] The observation of significantly higher MUFA level in mice fed ω-6
reflected the dietary composition of the ω-6 diet. Previous studies into the bioactivity of
olive oil showed that an iso-energetic MUFA diet can reduce liver fat in diabetic patients
[58], higher oxidation of MUFA in the liver of rats [59] and protects against experimental
inflammation [60]. Thus, we posit that our observations of inflammatory signals in ω-6 diet
fed mice is primarily due to changes in dietary ω-6: ω-3 or the absence of Lc- ω-3-PUFA,
rather than an increase in MUFA with the ω-6 diet. In our studies we measured the ω-3
PUFAs DHA and EPA in the livers of mice fed ω-3 and ω-6 diets. In a previous report, a
decrease in total hepatic ω-6 PUFA and AA levels were observed in a mouse model of
NAFLD, which was associated with the metabolic utilization of AA during chronic
inflammation.[61] The majority of dietary NAFLD studies have been based on obesity such
as the use of a model of over-consumption versus a control diet;[62] ad-libitum feeding of a
high saturated fat diet (>60% calories from fat)[26, 63] or a high fat Lieber-DeCarli diet
(71% of energy from fat) compared to the original Lieber-DeCarli control diet (35% fat, that
we used herein).[64] Thus, the role of PUFA composition, as opposed to obesity, in the
pathogenesis of “fatty liver” has to date been poorly evaluated. In these studies, we report an
increase in macro-vesicular steatosis in ω-6 diet fed mice, an observation consistent with
previous clinical and animal model studies, which emphasized that a western diet-induced
hepatic steatosis.[63, 65] However, unlike previous animal studies, we observed lower
relative liver weights and higher steatosis in the ω-6 diet fed mice,[63] supporting a role for
dietary PUFA composition on the hepatic microenvironment, independent of total caloric
intake.[66] Most studies used high fat/high caloric /high saturated fat diets to induce hepatic
steatosis and compared the results with liver from control mice fed a standard laboratory
chow diet, which has ω-6:ω-3 ratio of around 10:1 with variable dietary composition.[67,
68] The present study compared the results between two liquid diets differed in FA
composition only. Further, an increase in liver weights in diet induced NAFLD/NASH
studies might be a consequences of severe steatosis along with induction of fibrosis in liver.
Thus, it is possible that feeding the moderately fat ω-6 diet for 20 weeks may be insufficient
for the development of other NASH symptoms such as fibrosis, which might be responsible
for increasing liver weight in steatosis studies using NAFLD/NASH model. In this study, the
lobular hepatocytes from ω-6 diet mice lacked glycogen storage (Fig.3) which is supported
by the significant increase in macrosteatosis in lobular and portal regions of the ω-6 mice
(Fig. 2I). Hepatic steatosis and glycogen storage levels vary depending on the strain of mice
and the percent of glycogen positive cells decrease with an increase in steatosis in high fat
diet fed BALB/c mice.[69] Similarly, increased macrosteatosis in the livers of mice fed a
high carbohydrate diet was associated with a decrease in glycogen storage, which recoverd
by inclusion of ω-3 FA in the diet. [70] The difference in hepatic glycogen storage might be
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due to specific regulatory roles of ω-6 and ω-3 FA in metabolic pathways. [71] However, a
comparison of hepatic glycogen content between moderately fat, isocaloric, isolipidic and
pair-fed model has not been reported previously, suggesting a need for further studies to
understand the metabolic regulation of the diets which might have modulated mechanisms of
energy storage in the form of fat or glycogen. In summary, the decreased glycogen content
(Fig. 3), together with increased steatosis (Fig. 2), decreased hepatocyte proliferation and
increased hepatocyte apoptosis (Fig. 5) might contribute to the lower hepatic weight of the
ω-6 diet fed mice observed in the current study.
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In these studies, we observed a significant increase in hepatic inflammatory cells in an
absence of leukophilia in the ω-6 diet group suggesting that the outcome of higher number
of inflammatory cells in the liver was independent of a systemic inflammatory response.
Further, histological analysis documented a significant increase in the number and size of
inflammatory cell foci, containing immature myeloid cells in the livers of mice fed a high
ω-6:ω-3 diet. The foci closely resembles hepatic EMH as defined by National Toxicological
program [72] however, as majority of cells in the foci were early myeloid cells, likely
myeloid progenitor cells with a lack of erythroid progenitor cells [as defined in EMH], we
addressed the foci as EMM. We further confirmed the increase in hematopoietic progenitors
in livers of the ω-6 diet fed mice by flow analysis and CFU-GM counts. Unlike humans,
mice have a smaller medullary space resulting in EMH during early development; however,
our observation of a significant increase in number and size foci of EMM in 30 weeks old
mice fed an ω-6 diet compared to age matched ω-3 diet fed mice cannot be considered as a
normal developmental phenomenon and needs further evaluation. An increase in EMM foci
in association with hepatic steatosis has not been reported previously; however, prior hepatic
steatosis studies were based on a NASH model, which might have an infiltration of mature
inflammatory cells, such that enhanced EMM was obscured by regional inflammation.
Modulation of the hepatic microenvironment and the production of growth factors such as
granulocyte-monocyte colony stimulating factor (GM-CSF) by inflammatory cells may
result in EMM.[72] Further, our observation of degenerating hepatocyte morphology with
large lipid inclusions, higher numbers of apoptotic hepatocytes, and an increase in NFκB
levels support an inflammatory cell role in the modulation of the hepatic microenvironment
resulting in the mobilization of hematopoietic precursors leading to hepatic EMM in mice
fed a high ω-6:ω-3 PUFA diet.
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Hepatocyte proliferation [73] maintains hepatic mass and in our studies we observed
decreased hepatocyte proliferation in the ω-6 diet fed mice. However, this differs from a
previous report of an increased hepatocyte proliferation in NAFLD hepatic steatosis.[74]
The basis of this difference needs further evaluation, but likely contributes to the decreased
liver size in the ω-6 diet-consuming mice. Further, hepatocyte apoptosis is a prominent
clinical feature of NASH and positively correlates with hepatic inflammation.[30] Thus, the
observation of increased apoptotic hepatocytes in livers of mice fed ω-6 diet, steatosis and
EMM supports a role of for dietary PUFA in the initiation of liver inflammation.
The significant increase in bile duct diameters at comparable levels of the biliary tree and
morphological alterations on the biliary epithelium in mice fed ω-3 versus ω-6 diet may be
secondary to the changes in liver mass between the dietary groups (Fig. S2). However,
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additional mechanistic studies are needed to analyze a potential role for dietary PUFA on the
biliary system.
In summary, employing a pair fed, liquid diet with a lipid composition of 35% of dietary
calories, the present study demonstrates that consuming a high ω-6:ω-3 PUFA diet regulates
hepatic steatosis, EMM, glycogen deposition, and hepatocyte apoptosis. These results
indicate that dietary Lc PUFA ω-3 suppresses steatosis and prevents the “first hit”
mechanism of fatty liver development, and potentially lowers the risk of NAFLD and liver
injury associated hepatic disorders. This may support a role for a ω-6:ω-3 FA ratio, but not
the average calories consumed from fat, (∼35%) in the initiation of the formation of a “fatty
liver”. However, other attributes of metabolic changes due to hypercaloric consumption and
obesity might promote progression to NAFLD and NASH.
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AA

Arachidonic acid

CFU-GM

Colony forming unit-granulocyte-macrophage

DHA

Docosahexaenoic acid

EMH

Extramedullary hematopoiesis

EMM

Extramedullary myelopoiesis

EPA

Eicosapentaenoic acid

FA

Fatty acid

Lc

Long chain

MCV

Mean corpuscular volume

MUFA

Monounsaturated fatty acid

NAFLD

Non-alcoholic fatty liver disease

NASH

Non-alcoholic steatohepatitis

ORO

Oil Red O

PAS

Periodic Acid-Schiff

PAS-Digest

Periodic Acid-Schiff-Diastase

PUFA

Polyunsaturated fatty acid

RBC

Red blood cell
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SFA

Saturated Fatty Acid
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Figure 1. Isocaloric and isolipidic diets, pair-fed model and their impact on body weight

Author Manuscript

Mice were pair-fed omega- (ω-6) and omega-3 (ω-3) PUFA diets for 10 or 20 weeks.
Experimental design for a pair-fed model (A). Mice were acclimatized to liquid diets by
feeding ad libitum amounts for the first five days. Thereafter, the ω-6 diet group mice were
pair-fed based on the diet consumed by the ω-3 mice on a cage basis on the preceding day.
The average amount of diet consumed/day (B). Differences in percent changes in body
weights between the pair-fed groups [n= 20] compared by a repeated measure test (C). Body
weights before the start of the liquid diet [day 0], at the start of pair-feeding [day 5], on day
20, and day 40, of pair feeding and before autopsy on [day 69] (n=20) (D). Comparison of
abdominal adipose tissues between the groups (E and F) (n=3), based on abdominal fat
weight (E), as well as, fat weight relative to body weight (%) at autopsy (F). Photographs of
representative livers document differences in color and size from mice fed ω-3 (G) or ω-6
(H) diets. Comparison of liver weight (I) and liver weight relative to body weight (J) (n=3).
* = p ≤ 0.05
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Figure 2. Differential effects of dietary PUFA on hepatic steatosis

Hepatic steatosis analysis of livers by H & E staining (A). Oil Red O-stained liver sections
analyzed for hepatic steatosis (B and C). Images were taken with magnification of 400× (A)
and 1000× (B) (n=5) [*=p<0.05].
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Figure 3. Differential regulation of hepatic glycogen storage by dietary PUFA

Liver sections stained with Periodic Acid-Schiff (PAS) showed glycogen-containing
hepatocytes around the regions of central vein and portal area of hepatic lobules in mice fed
ω-3 diet but absent in ω-6 diet group (A and B). The hepatic glycogen was digested using
PAS-diastase staining (PAS-Digest) (C). Images were taken with magnification of 200× (A
and C) and (n=5) [*=p<0.05].
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Figure 4. Differential regulation of hepatic extramedullary myleopoeisis (EMM) by PUFA

Author Manuscript

Livers of mice were compared for hepatic EMM by counting the number and size of EMM
foci in 10 microscopic fields/sample by H & E staining (A) (n= 3 to10). Arrows indicate a
focus of EMM. Comparison of EMM foci between 10 weeks and 20-week diet fed mice of
the dietary groups (B). Analysis of 100× magnified fields of CD45 stained liver sections for
CD45+ single cells (C and D). Analysis of number and size of CD45+ cell clusters in dietary
groups (E, F, and G). Images were taken at a magnification of 400× (A) and 100× (C and E).
Hepatic NF kB protein expression was significantly higher in the ω-6 as assessed based on
Western blots (H and I) [*=p<0.05].
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Figure 5. Dietary PUFA regulation of hepatocyte proliferation, and apoptosis

The livers of mice fed ω-3 and ω-6 diets for 20 weeks were compared based on proliferation
(Ki67) and apoptosis (TUNEL) by counting the number of positive cells per 10 microscopic
fields per sample (n=3). The number of proliferating hepatocytes observed are shown in A
and B. The number of TUNEL+ (apoptotic) nuclei (C and D) and apoptotic nuclei relative to
total nuclei (C and E) observed in are shown. Images were taken at a magnification of 100×
(A) and 630× (C) respectively [*=p<0.05].
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Table 1

Composition of the experimental diets
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The omega-6 diet (ω-6 diet) is the Lieber-Decarli control diet, which contains 28.4 gm/L of olive oil. Omega-3
diet (ω-3 diet) was customized by replacing 20 gm/L olive oil with the ω-3 oil (NutriGold omega 3 capsule).
All the other components were the same in both of the diets to maintain iso-composition and isocaloric
properties.

Author Manuscript

ω-6 Diet Grams/L

ω-3-Diet Grams/L

Casein

41.4

41.4

L-Cystine

0.5

0.5

DL-Methionine

0.3

0.3

Corn Oil

8.5

8.5

Olive Oil

28.4

8.4

Safflower Oil

2.7

2.7

115.2

115.2

10

10

Mineral Mix

8.75

8.75

Vitamin Mix

2.5

2.5

Choline Bitartrate

Ingredient in Diet

Maltose Dextrin
Cellulose

0.53

0.53

Xanthum gum

3

3

Encapsulated omega-3 oil

0

20

221.8

221.8

Total
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7.18
10.56
4.72
1.81

Total omega 6 FA level
Total omega 3 FA level
Total MUFA level
Total SA level
Total Fatty Acid Concentration (μg/mg or μg/uL)

2.64

cis-4,7,10,13,16,19-Docosahexaenoic (DHA) (ω-3)

22:6

24.27

0.26

0.25

7.52

0.51

0.00

0.70

cis-4,7,10,13,16-Docosapentaenoic acid (ω-3)

cis-13-Eicosenoic

20:1

0.14

22:5

cis-9,12,15-Octadecatrienoic acid (Linolenic) (ω-3)

18:3

6.67

13-Docosenoic acid

cis-8,11-Octadecadienoic (Linoleic) (ω-6)

18:2

3.77

22:1

9-Octadecenoic

18:1

0.28

0.00

cis-5,8,11,14,17-Eicosapentaenoic (EPA) (ω-3)

Octadecanoic

18:0

20:5

9-Hexadecenoic

16:1

1.53

0.00

cis-7,10,13-Eicosatrienoic

Hexadecanoic

cis-5,8,11,14-Eicosatetraenoic (AA) (ω-6)

Tetradecanoate

14:0

16:0

ω3

20:4

ω6

ω3

25.07

3.98

15.82

0.24

5.03

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.24

5.03

15.62

0.76

0.20

3.02

0.20

ω6

Diet (μg/μl)

20:3

Fatty Acid (FA) Name

Carbon chain length and double bonds

2.32 ± 0.16

1.37 ± 0.16

0.23 ± 0.02

0.33 ± 0.01

0.39 ± 0.01

0.14 ± 0.01

0.00 ± 0.00

0.02 ± 0.02

0.19 ± 0.01

0.08 ± 0.01

0.00 ± 0.00

0.01 ± 0.01

0.00 ± 0.00

0.31 ± 0.01

0.20 ± 0.01

0.57 ± 0.14

0.00 ± 0.00

0.79 ± 0.08

0.01 ± 0.01

ω3

5.58 ± 1.07

7.91 ± 0.73
24.35 ± 3.13
9.55 ± 0.91

1.08 ± 0.04 *
0.05 ± 0.01 *
0.36 ± 0.02 *

2.66 ± 0.11

60.00 ± 5.49

17.50 ± 4.35

16.55 ± 2.92

0.05 ± 0.01 *

1.17 ± 0.10

2.22 ± 0.33

0.00 ± 0.00

0.09 ± 0.09

2.13 ± 0.38
0.00 ± 0.00 *
0.00 ± 0.00

0.69 ± 0.21
0.64 ± 0.03 *

0.10 ± 0.10

0.00 ± 0.00

0.00 ± 0.00

0.00 ± 0.00

0.00 ± 0.00

5.78 ± 0.62

8.35 ± 0.85

0.35 ± 0.02 *
0.44 ± 0.03

5.18 ± 1.42

1.01 ± 0.29

12.32 ± 4.12

0.00 ± 0.00

17.97

0.68 ± 0.08 *

85.20 ± 3.49

21.02 ± 1.32

45.15 ± 3.12 *

2.18 ± 0.10 *

16.36 ± 0.85 *

706.40

9.65

66.97

587.45

42.33

159.78

12.54

1.50 ± 0.06 *

409.70
0.00 ± 0.00 *

37.60
0.00 ± 0.00 *

5.14 ± 0.20 *

0.00

26.99

0.86 ± 0.05 *
0.49 ± 0.04

0.00

4.73

11.22 ± 0.83 *
0.00 ± 0.00

27.44

0.00

0.00

9.65

0.00

Fish Oil (μg/μl)

42.87 ± 3.11 *

5.19 ± 0.21

1.42 ± 0.18

15.83 ± 1.30

0.00 ± 0.00

Liver (μg/mg ± SEM)

0.38 ± 0.01

0.01 ± 0.01

0.79 ± 0.10

0.00 ± 0.00

ω6

Plasma (μg/μl ± SEM)

Concentration

ω-6 vs. ω-3 diets were freshly prepared daily using ready to feed liquid diets. The fish oil used was from pharmaceutical grade ω-3 capsules. Liver and
plasma were collected from the mice fed respective diets for 10 weeks. (n=5) The average liver weights for the two groups were significantly different
(ω-3> ω-6) and are shown in figure 1G and 1H

Fatty acid profiles of diets, liver, and plasma measured by gas chromatographic mass spectrophotometry (GC-MS) analysis
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=p<0.05.

*

Ratio of total ω-6 FA to ω-3 FA (ω-6:ω-3)

ω6

Author Manuscript
ω3

Author Manuscript
Fatty Acid (FA) Name

0.7:1

ω3
21:01

ω6

Diet (μg/μl)

1.2:1

ω3
21.6:1 *

ω6

Plasma (μg/μl ± SEM)

Author Manuscript

Carbon chain length and double bonds

0.32:1

7.5:1 *

Liver (μg/mg ± SEM)
Fish Oil (μg/μl)
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